Table 2 Multivariable analyses of risk factors for an impairment caused by reactogenicity or incapacity to work (single vaccinations)
Variable | OR (95% confidence interval) | P -value |
|---|---|---|
Assumed grade of impairment caused by reactogenicity OR represents the odds ratio for a higher grade of impairment (i.e., significant vs. mild/none, significant/mild vs. none). Based on 12,387 vaccinations with complete information | ||
Age (31–40 vs. 18–30) | 0.80 (0.71–0.90) | < .001 |
Age (41–50 vs. 18–30) | 0.64 (0.57–0.71) | < .001 |
Age (51–60 vs. 18–30) | 0.46 (0.41–0.52) | < .001 |
Age (> 61 vs. 18–30) | 0.35 (0.30–0.41) | < .001 |
Time of vaccination (afternoon vs. morning) | 1.04 (0.96–1.12) | ns |
Male gender | 0.66 (0.58–0.76) | < .001 |
Vaccination (second vs. first) | 2.00 (1.75–2.29) | < .001 |
Vaccine (ChAdOx vs. BNT162b2) | 2.43 (2.16–2.74) | < .001 |
Vaccine (mRNA-1273 vs. BNT162b2) | 2.08 (1.72–2.51) | < .001 |
Male gender × Vaccination (second vs. first) | 1.06 (0.89–1.25) | ns |
Male gender × Vaccine (ChAdOx vs. BNT162b2) | 1.03 (0.84–1.26) | ns |
Male gender × Vaccine (mRNA-1273 vs. BNT162b2) | 0.73 (0.50–1.06) | ns |
Vaccination (second vs. first) × Vaccine (ChAdOx vs. BNT162b2) | 0.05 (0.04–0.06) | < .001 |
Vaccination (second vs. first) × Vaccine (mRNA-1273 vs. BNT162b2) | 1.50 (1.08–2.08) | .017 |
Duration of an incapacity to work OR represents the odds ratio for a longer incapacity to work (i.e., ≥ 3 days vs. 0–2 days, ≥ 1 days vs. none) Based on 11,105 vaccinations with complete information | ||
Age (31–40 vs. 18–30) | 0.68 (0.58–0.78) | < .001 |
Age (41–50 vs. 18–30) | 0.59 (0.51–0.67) | < .001 |
Age (51–60 vs. 18–30) | 0.47 (0.41–0.54) | < .001 |
Age (> 61 vs. 18–30) | 0.50 (0.40–0.62) | < .001 |
Time of vaccination (afternoon vs. morning) | 1.08 (0.97–1.19) | ns |
Male gender | 0.72 (0.61–0.85) | < .001 |
Vaccination (second vs. first) | 1.59 (1.30–1.96) | < .001 |
Vaccine (ChAdOx vs. BNT162b2) | 2.12 (1.76–2.54) | < .001 |
Vaccine (mRNA-1273 vs. BNT162b2) | 1.87 (1.42–2.46) | < .001 |
Male gender × vaccination (second vs. first) | 0.88 (0.65–1.19) | ns |
Male gender × vaccine (ChAdOx vs. BNT162b2) | 1.33 (0.90–1.97) | ns |
Male gender × vaccine (mRNA-1273 vs. BNT162b2) | 1.17 (0.73–1.987) | ns |
Vaccination (second vs. first) × vaccine (ChAdOx vs. BNT162b2) | 0.05 (0.03–0.06) | < .001 |
Vaccination (second vs. first) × vaccine (mRNA-1273 vs. BNT162b2) | 1.09 (0.68–1.75) | ns |